Lightship Raises $40 Million to Revamp How Drugs Are Studied and Approved

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

telehealth telemedicine generic
As the pandemic slowed and halted clinical trials to test new drugs, the need for a virtual solution became clear to clinical researchers. El Segundo-based Lightship hopes to keep clinical trials going with a virtual process that allows patients to participate from home.

The three-year-old company is one of many in Los Angeles, including MedVector and Science37, investing in a new model of clinical drug trials that seek to virtualize and speed up a yearslong, data-intensive process heavily regulated by the Food and Drug Administration. Those trials are key to help doctors understand the efficacy and side effects of drugs before dosing their patients.

The approach has proved attractive during a pandemic that has forced traditional drug trials to slow down as researchers scrambled to safely conduct trials without putting participants in danger of COVID-19.

SEC filings from Monday show the startup raised $40 million from 10 undisclosed investors. Neither Lightship nor its previous investors responded to requests for comment.

But the move comes as the Food and Drug Administration shifts its thinking on clinical trials. In November, the agency updated its standards to accommodate patients participating in clinical trials from home. It also acknowledged the process was largely unfair because it failed to include underrepresented patients.

In issuing the guidance, Commissioner Stephen M. Hahn acknowledged "clinical trials requiring frequent visits to specific sites may place an added burden on participants."

The clinical trial process often excludes underprivileged people who would otherwise be prime candidates for the drug. That's because it requires participants to drive to hospitals or research sites, sometimes during the work day.

Lightship, though tight-lipped about its products, says on its website it aims to construct flexible clinical trial solutions for companies that want to accommodate patients that can't drive to a nearby facility for regular testing.

That could help clinical trials solve their diversity problem that some researchers argue have plagued the industry.

Clinical trials depend on racial and financial diversity because a drug's efficacy isn't based solely on the chemical composition of the drug – it also requires an extensive understanding of different environmental factors, such as someone's quality of sleep, outside stressors and genetics. Those factors can influence a drug's performance and they are part of what the FDA considers when it creates a drug's safety profile for doctors and patients before releasing the drug onto the market.

"If you don't include a diverse population in your clinical trial and really study those differences or similarities, you might end up having a situation where the product is out in the market and it has a different safety and efficacy profile [than what was originally written]," said Dr. Eunjoo Pacifici, a professor at the USC School of Pharmacy.

Lightship previously raised $10 million in a debt financing round in April, and nearly $20 million in venture capital in 2020.

MedVector, another LA-based startup tackling the virtual clinical trial space, raised $630,000 in March for a product to help clinicians document a participant's vitals without requiring them to travel. Another, Science 37, raised $40 million in 2020 to construct flexible clinical trials.
https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

Henrik Fisker Says Tesla Price Cuts Haven’t Fazed Ocean Rollout

David Shultz

David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.

A Fisker electric vehicle.​
Courtesy of Fisker

Last week in the dot.LA newsletter I wrote about Tesla’s decision to slash prices by as much as 20% on their vehicles and how the decision might impact Southern California’s EV startups. I called the price cuts a “tough pill to swallow” for Fisker in particular since they would make many of Tesla’s price points more competitive with Fisker’s first production model, The Ocean.

The Ocean is currently undergoing homologation, but Henrik Fisker, the company’s CEO, confirmed to dot.LA that the company hopes the process to be completed at the end of February. From there, it could take several weeks to ship the SUVs from Austria to the United States.

Read moreShow less

Diankha Linear on How Community Is Revolutionizing Text Marketing

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Diankha Linear
Diankha Linear

On this episode of Office Hours, Community CEO Diankha Linear joins host Spencer Rascoff to discuss her foray into the startup world and the strategic approaching to scaling up.

Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending